LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Apellis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

17.41 -5.38

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.35

Максимум

18.37

Ключови измерители

By Trading Economics

Приходи

-56M

-92M

Продажби

-46M

167M

EPS

-0.74

Марж на печалбата

-55.292

Служители

705

EBITDA

-56M

-80M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+93.75% upside

Дивиденти

By Dow Jones

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-333M

2.2B

Предишно отваряне

22.79

Предишно затваряне

17.41

Настроения в новините

By Acuity

50%

50%

154 / 380 Класиране в Healthcare

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.06.2025 г., 23:49 ч. UTC

Печалби

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26.06.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26.06.2025 г., 21:30 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26.06.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26.06.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26.06.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26.06.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers Will No Longer Receive Earnings From BWP Management

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26.06.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26.06.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26.06.2025 г., 23:19 ч. UTC

Придобивния, сливания и поглъщания

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26.06.2025 г., 22:06 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:15 ч. UTC

Печалби

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26.06.2025 г., 21:06 ч. UTC

Пазарно говорене

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 20:52 ч. UTC

Печалби

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26.06.2025 г., 20:51 ч. UTC

Печалби

Correct: Nike 4Q Net $211M, Not $200M >NKE

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

93.75% нагоре

12-месечна прогноза

Среден 35.65 USD  93.75%

Висок 60 USD

Нисък 18 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

10

Купи

8

Задържане

0

Продай

Настроение

By Acuity

154 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.